HebeCell develops universal and cost-effective NK cell therapeutics from a proprietary 3D-pluripotent stem cell (PSC) platform to create off-the-shelf CAR-NK products. The company aims to establish a master PSC-CAR cell bank targeting multiple specific antigens to provide inexhaustible allogeneic cell sources. Its lead programs target cancer, viral infection, and autoimmune diseases and the company plans IND filing and clinical advancement. The recent $53 million Series A will be used to accelerate R&D, IND filing, clinical application, marketing, and global expansion. HebeCell was founded in 2016 and operates a state-of-the-art R&D and GMP facility in Natick, MA, and is actively recruiting R&D and GMP scientists. The company is partnering with Jacobio to leverage complementary strengths and advance next-generation PSC-CAR-NK therapies to market.

Total raised

$53M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2021